US FDA seeks input on role of patients in RnD, regulatory processes
This article was originally published in SRA
Executive Summary
Patients are becoming increasingly involved in the medical product R&D and regulatory processes, with advocacy groups – especially those in the rare disease community – demanding a seat at the table and seeking to influence how and when medicines enter the marketplace.